LONDON, June 2 (Reuters) - The European Medicines Agency has recommended approval of Johnson & Johnson’s (JNJ.N: Quote, Profile, Research) Doribax for hospital-aquired pneumonia, complicated intra-abdominal infectiond and complicated urinary tract infections. The London-based watchdog said on Monday its approval was for adults. Recommendations for marketing approval by the agency’s Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
